IBIO
Earnings company data as of 4:48 AM ET 10/23
Scheduled
2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 4 Sep | EPS | -0.06 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by IBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $98K bought by 3 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Marc Banjak Chief Legal OfficerBuy$23K 13,934 shares at $1.65 +126% to stakeTraded Mar 26 Filed Mar 27
-
Felipe Duran CFOBuy$50K 24,835 shares at $2.02 +223% to stakeTraded Mar 19 Filed Mar 23
-
Martin Brenner See RemarksBuy$25K 12,336 shares at $2.02 +67% to stakeTraded Mar 19 Filed Mar 23
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02,5.03,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02,8.01,9.01 | Filing Doc | |
| 8-K | 5.08,8.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| 424B3 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.